[Drug therapy for acromegaly].
Prolonged overproduction of growth hormone, like insulin-like growth factor-1 hypersecretion leads to acromegaly in adults. This is associated with several co-morbidities and increased mortality. Despite typical clinical features and modern diagnostic tools, it often takes years to diagnose from the onset of the disease. The aims of the treatment are to reduce or control tumour growth, inhibit growth hormone hypersecretion, normalize insulin-like growth factor-1 levels, treat co-morbidities and, therefore, reduce mortality. There are three approaches for therapy: surgery, medical management (dopamine agonists, somatostatin analogues and growth hormone receptor antagonist), and radiotherapy. Efficient therapy of the disease is based on the appropriate multidisciplinary team management. The review provides a summary of medical treatment for acromegaly.
Magyar Honvédség Egészségügyi Központ II. Belgyógyászati Osztály, Endokrinológiai Szakprofil Budapest Podmaniczky u. 111. 1062.
Miklós
M
Góth
D000172:Acromegaly / Q000209:etiology; D000634:Aminoquinolines / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D033183:Interdisciplinary Communication; D008565:Membrane Proteins / Q000037:antagonists & inhibitors*; D015282:Octreotide / Q000627:therapeutic use; D010348:Patient Care Team; D010456:Peptides, Cyclic / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism; D013004:Somatostatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000634:Aminoquinolines; D018931:Antineoplastic Agents, Hormonal; D018491:Dopamine Agonists; D004873:Ergolines; D008565:Membrane Proteins; D010456:Peptides, Cyclic; C405010:delta-hGHR; C060347:lanreotide; D019382:Human Growth Hormone; D001971:Bromocriptine; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; C046650:quinagolide; C517782:pasireotide; D000077465:Cabergoline; C406545:pegvisomant; D015282:Octreotide